s6y

Vaxart, Inc.

Ticker
VXRT
CIK
72444
Industry
Biological Products, (No Diagnostic Substances)
Formerly
Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC

Financials 135

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K/A Annual Report for period ending Dec 31, 2025
  5. 10-K Annual Report for period ending Dec 31, 2025
  6. 10-Q Quarterly Report for period ending Sep 30, 2025
  7. 10-Q Quarterly Report for period ending Jun 30, 2025
  8. 10-Q Quarterly Report for period ending Mar 31, 2025
  9. 10-K Annual Report for period ending Dec 31, 2024
  10. 10-Q Quarterly Report for period ending Sep 30, 2024

All 135 financials filings

News 404

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 404 news filings

Ownership 728

  1. 4 Statement of changes in beneficial ownership of securities
  2. 3 Initial statement of beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 728 ownership filings

Prospectus 203

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. S-1/A General form of registration statement for all companies including face-amount certificate companies
  3. S-1 General form of registration statement for all companies including face-amount certificate companies
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. S-3 Registration statement for specified transactions by certain issuers
  6. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  9. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  10. 424B5 Prospectus filed pursuant to Rule 424(b)(5)

All 203 prospectus filings

Proxies 167

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  3. DFAN14A Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
  4. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. DFAN14A Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 167 proxies filings

Other 136

  1. ARS Annual report to security holders
  2. EFFECT Notice of Effectiveness
  3. EFFECT Notice of Effectiveness
  4. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  5. UPLOAD Letter (PDF)
  6. 144 Filing for proposed sale of securities under Rule 144
  7. 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  8. PX14A6G Notice of exempt solicitation
  9. PX14A6G Notice of exempt solicitation
  10. PX14A6G Notice of exempt solicitation

All 136 other filings